Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ASCO relevance

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 29, 2023 10:26pm

148 Views

Post# 35421300

RE:RE:RE:RE:ASCO relevance

Furthermore the PD-(L)1 checkpoint inhibitor market will be in excess of US$120 Billion by 2027 which ONCY is seeking to expand by making these checkpoint inhibitors 2-3x more effective.

And if you Geneman had kept up with the changes in the IO space you would have known this but instead of your own DD you think that now we are going to feed you information to bring you up to speed to facilitate your investment decisions. WRONG dear Geneman.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism